Entities / Company
Akebia Therapeutics (United States).
company in Cambridge, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 35
What's happening
Gone quiet
No new reports in 90+ days-
Tariffs and onshoring trends are benefiting AI stocks, while a company acquisition enhances its liver disease portfolio, aided by a breakthrough designation.Some support7 reports4 developments inside
-
Akebia Therapeutics' earnings outlook improved and was noted for outperforming peers, while ResMed was also reported for outperforming the medical sector.Some support1 report
-
Akebia Therapeutics is providing Vafseo for kidney disease treatment, which Innovative Renal Care has made available across all clinics.Some support6 reports1 development inside
-
Akebia Therapeutics appointed Myles Wolf as a Class II director and selected Ernst & Young LLP as its independent public accounting firm.Speculative1 report
-
Akebia Therapeutics received a rating change following an upward trend in its earnings estimates, which institutional investors use for valuation.Some support2 reports
-
DaVita is starting an operational pilot for Vafseo, and Akebia expects IRC to operationalize the Vafseo protocols.Some support1 report1 development inside
-
Akebia Therapeutics conducted a study within DaVita clinics on August 4, 2025.Some support1 report
-
Akebia Therapeutics (a company in the US) achieved profitability due to higher revenue on August 9, 2025.Some support1 report
-
Akebia Therapeutics and GRUND, along with Erik Ostrowski, are scheduled to present at various conferences in Boston on August 28, 2025.Some support1 report
-
Akebia Therapeutics is headquartered in Cambridge, Massachusetts.Some support7 reports
No events began in the chosen period. Widen it, or reset.
Around Akebia Therapeutics (United States) this week
News at the entities that move Akebia Therapeutics (United States) most-
Cambridge Shared contextCambridge is attracting talent and innovation, with AI and tech companies driving demand for office space.Moves Akebia Therapeutics (United States)
Connections
The 1 strongest of 35, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Cambridge Shared context
Akebia Therapeutics is headquartered in Cambridge, Massachusetts.
History
Events by the month they beganJune 2026
10 events- Tariffs and onshoring trends are benefiting AI stocks, while a company acquisition enhances its liver disease portfolio, aided by a breakthrough designation.
- Akebia Therapeutics' earnings outlook improved and was noted for outperforming peers, while ResMed was also reported for outperforming the medical sector.
- Akebia Therapeutics is providing Vafseo for kidney disease treatment, which Innovative Renal Care has made available across all clinics.
- Akebia Therapeutics appointed Myles Wolf as a Class II director and selected Ernst & Young LLP as its independent public accounting firm.
- Akebia Therapeutics received a rating change following an upward trend in its earnings estimates, which institutional investors use for valuation.
- DaVita is starting an operational pilot for Vafseo, and Akebia expects IRC to operationalize the Vafseo protocols.
- Akebia Therapeutics conducted a study within DaVita clinics on August 4, 2025.
- Akebia Therapeutics (a company in the US) achieved profitability due to higher revenue on August 9, 2025.
- Akebia Therapeutics and GRUND, along with Erik Ostrowski, are scheduled to present at various conferences in Boston on August 28, 2025.
- Akebia Therapeutics is headquartered in Cambridge, Massachusetts.